During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
|Articles|December 17, 2013
- Melanoma (Issue 1)
- Volume 1
- Issue 1
The Outlook for BRAF Inhibitors in Melanoma
Author(s)Antoni Ribas, MD, PhD
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the outlook for BRAF inhibitors in melanoma.
Advertisement
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the outlook for BRAF inhibitors in melanoma.
Read more about BRAF inhibitors for the treatment of melanoma and
Articles in this issue
almost 13 years ago
Two BRAF Fusions Discovered in Some Pan-Negative Melanomasalmost 13 years ago
Understanding the Biologic Pathways in Basal Cell Carcinomaalmost 13 years ago
Advances in Metastatic Melanomaalmost 13 years ago
Targeted Therapies in Basal Cell Carcinomaalmost 13 years ago
The Treatment of Melanoma With Emerging Targeted TherapiesAdvertisement
Related to this article
The investigational chemoimmunotherapy antibody-drug conjugate demonstrated enhanced tumor inhibition in preclinical models.
Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone and in key first-line combinations.
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.
Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5